TY - JOUR
T1 - In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)
AU - Soto, Claudia
AU - Du, Huang Chi
AU - Fox, Robert
AU - Yang, Taegyun
AU - Hooson, James
AU - Anastasio, Noelle C.
AU - Gilbertson, Scott R.
AU - Cunningham, Kathryn A.
AU - Gilbertson, Scott R.
N1 - Publisher Copyright:
© 2019 Frontiers Media S.A.. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.
AB - Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.
KW - Drug discrimination
KW - Peptidomimetics
KW - Protein phosphatase and tensin homolog
KW - Protein-protein interactions
KW - Serotonin 2C receptor
UR - http://www.scopus.com/inward/record.url?scp=85070718619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070718619&partnerID=8YFLogxK
U2 - 10.3389/fphar.2019.00907
DO - 10.3389/fphar.2019.00907
M3 - Article
C2 - 31507411
AN - SCOPUS:85070718619
SN - 1663-9812
VL - 10
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - JULY
M1 - 907
ER -